Last reviewed · How we verify
Sodium hyaluronate 0.15%
Sodium hyaluronate is a viscoelastic substance that lubricates and protects the ocular surface by mimicking natural tear film.
Sodium hyaluronate is a viscoelastic substance that lubricates and protects the ocular surface by mimicking natural tear film. Used for Dry eye syndrome, Ocular surface protection during ophthalmic surgery, Post-operative ocular surface care.
At a glance
| Generic name | Sodium hyaluronate 0.15% |
|---|---|
| Also known as | Hyabak® PF |
| Sponsor | Laboratorios Sophia S.A de C.V. |
| Drug class | Artificial tear / Ocular lubricant |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Sodium hyaluronate is a naturally occurring polysaccharide that acts as a humectant and lubricant on the eye surface. It binds water molecules and forms a protective layer over the cornea and conjunctiva, reducing friction and providing sustained hydration. This mechanism makes it effective for treating dry eye and protecting the ocular surface during and after ophthalmic procedures.
Approved indications
- Dry eye syndrome
- Ocular surface protection during ophthalmic surgery
- Post-operative ocular surface care
Common side effects
- Mild ocular irritation
- Transient blurred vision
- Foreign body sensation
Key clinical trials
- Comparison of Ocular Lubricants in People With Symptoms of Dry Eye (PHASE4)
- Study to Compare the Efficacy of the Ophthalmic Solution Humylub Ofteno® PF With Hyabak® and Lagricel Ofteno® PF as Treatment for Dry Eye. (PHASE4)
- Protecting the Eyes of Gamers With Lubricating Eyedrops (NA)
- Cord Blood Platelet Poor Plasma Eye Drops (NA)
- Potential Role of Ocular Surface Microbiome in Dry Eye: Microbial Interactions and Symptom Alleviation (NA)
- Clinical Study to Evaluate the Safety and Tolerability of PRO-229 Ophthalmic Solution Compared to Lagricel® Ofteno PF (PHASE1)
- Evaluation of Dexpanthenol and Hyaluronic Acid Eye Drops on Corneal Epithelialization After Trans Epithelial PRK (PHASE4)
- Performance and Safety Assessment of T2769 in Contact Lens Wearers With Dry Eye Symptoms. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sodium hyaluronate 0.15% CI brief — competitive landscape report
- Sodium hyaluronate 0.15% updates RSS · CI watch RSS
- Laboratorios Sophia S.A de C.V. portfolio CI